Written by Targeting anti-cancer therapy to affect cancer cells but not healthy cells is challenging. For chimeric antigen receptor (CAR) T–cell immunotherapy, where a patient’s own immune cells are re-engineered to attack cancer cells, many solid and brain cancers lack an effective target.
Medical Xpress – latest medical and health news stories